Phosphorylated eIF2α predicts disease-free survival in triple-negative breast cancer patients

Citations Over TimeTop 13% of 2017 papers

Abstract

Phosphorylated eukaryotic translation initiation factor 2α (p-eIF2α), which functions as a marker of endoplasmic reticulum stress, has been reported to be associated with patient prognosis in various cancers. However, little is known about the prognostic value of p-eIF2α in breast cancer, particularly in different breast cancer subtypes. An immunohistochemistry screen for p-eIF2α was performed using a tissue microarray containing 233 tumors and paired peritumoral tissues from female patients diagnosed with breast cancer. The staining results were scored semiquantitatively, and the p-eIF2α expression level in breast cancer and its potential prognostic value were investigated. In this retrospective cohort study, we found that p-eIF2α levels were significantly upregulated in breast cancer (P < 0.001). p-eIF2α level was negatively correlated with lymph node status (P = 0.039). Survival analysis by Kaplan-Meier estimation and Cox regression showed that p-eIF2α level was correlated with better disease free survival (P = 0.026) and served as an independent prognostic factor (P = 0.046) in patients with triple-negative breast cancer. Our study revealed that p-eIF2α was upregulated in breast cancer and represented a novel predictor of prognosis in patients with triple-negative subtype.

Related Papers

• → A comparison of triple negative versus triple positive breast cancers(2011)
• A validation study on tissue microarrays(2005)
• → COMPARISON OF CLINICO-PATHOLOGICAL FEATURES AND PROGNOSIS OF TRIPLE-NEGATIVE AND NON-TRIPLE-NEGATIVE FEMALE BREAST CANCER PATIENTS(2018)
• → Treatment of triple negative breast cancer(2013)
• → PO121 A COMPARISON OF CLINICOPATHOLOGICAL FEATURES AND PROGNOSIS BETWEEN TRIPLE-NEGATIVE AND NON-TRIPLE NEGATIVE BREAST CANCER AT OCEAN ROAD CANCER INSTITUTE(2023)